Bringing intelligence to genetic data
We are also expanding the way we communicate genetic test results, with the use of web apps.
The company has already started its internationalisation process and has a presence in Portugal, Spain, Italy and Brazil. In 2018, the company will start sales in Poland and Germany, and expand the business in Europe while consolidating sales in existing markets.
Results to date:
In the past two years, Heartgenetics has:
- developed two genetic tests for lifestyle (nutrition and fitness), including a web app for nutrition;
- launched three pharmacogenetics tests for cardiology;
- launched a genetic test for colon cancer pharmacogenetics;
- had our products certified CE-IVD;
- started sales in Spain;
- entered a partnership to pilots in Poland and Germany.
They have also been awarded the following certifications: ISO 9001, ISO 13485, NP 4457, UK NEQAS.
HeartGenetics’ secret is the combination of proprietary algorithms, new genetic tests, and a scalable methodology.
Benefits of EIT Health support
Anna Teresa Freitas, CEO of Heartgenetics, explains how EIT Health supports the company: “For Heartgenetics, being selected to participate in EIT Health GoEurope 2016, meant that we were awarded with a €50k grant that allowed us to fund a market study for evaluating the cardiovascular genetics market in Europe, which in turn enabled us to realign our strategy for European markets. The programme also gave us access to a greater network of Portuguese start-ups and entrepreneurs and access to EIT Health partners across Europe.
“The programme enabled us to participate in a one-week immersion programme in the Silicon Valley ecosystem. Through EIT Health GoGlobal, we also had the opportunity to pitch at TRACTION which is the Health 2.0 conference start-up championship. We were the only European company to do so that year. The information and evidence gathered through these experiences guided HeartGenetics to the decision to focus on developing the new vertical of wellness genetics, on brand recognition and European expansion rather than entering the US market immediately. The EIT Health programme supported us in this path towards greater maturity and sustainability.”